It’s utilizing Abbott’s cheaper Lingo sensors.
Ultrahuman is as we speak asserting M2 Reside, its second-generation steady glucose monitoring platform for the US with a less expensive worth. It’s going to even be far cheaper and simpler to get entry to, opening up the system to way more individuals, particularly as utilizing one is turning into far more widespread amongst non-diabetics. Primarily, whereas it is Ultrahuman promoting you the product, you are truly simply shopping for entry to certainly one of Abbott’s medical-grade CGMs. M1 Reside used Abbott’s Freestyle Libre, solely accessible within the US with a prescription and a far larger price than it’s in different territories. M2 Reside, in the meantime, harnesses Abbott’s over-the-counter Lingo monitor, which syncs with the Ultrahuman app to mesh its knowledge with no matter your ring is choosing up.
Very similar to its rivals on this house, Ultrahuman’s pitch is that your glucose knowledge is a great tool that may and must be mixed together with your activity stats. In spite of everything, how a lot sleep you get, stress you endure and train you do every day will inform how your physique handles glucose. The insights from all of this will likely be crunched by Jade, Ultrahuman’s AI, to supply up a metabolic rating, supplying you with steerage on what you are doing and the place you may enhance.
Ultrahuman M2 Reside will likely be accessible within the US within the “coming weeks,” with a single sensor — which you should use for 14 days — priced at $129. A month-to-month subscription, in the meantime, is priced at $99 per 30 days.
